| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 08/30/2001 | WO2001062275A1 Adjuvant treatment by in vivo activation of dendritic cells |
| 08/30/2001 | WO2001062239A2 Novel compositions and uses of dictyostatin compounds |
| 08/30/2001 | WO2001062233A2 Adenosine receptor modulators |
| 08/30/2001 | WO2001062092A1 Formulations and methods for using the same to elicit an immune response |
| 08/30/2001 | WO2001014408A3 Method for coupling, in solution, a peptide with at least another compound and uses thereof |
| 08/30/2001 | WO2001012776A3 18 human secreted proteins |
| 08/30/2001 | WO2001012606A3 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 08/30/2001 | WO2001002540A3 Adenoviral vectors for treating disease |
| 08/30/2001 | WO2000040733A9 Human cyclic nucleotide pdes |
| 08/30/2001 | WO2000040597A9 Method and composition for angiogenesis inhibition |
| 08/30/2001 | US20010018521 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives |
| 08/30/2001 | US20010018456 Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis |
| 08/30/2001 | US20010018451 Raloxifene, tamoxifen |
| 08/30/2001 | US20010018447 Il-8 receptor antagonists |
| 08/30/2001 | US20010018443 Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds |
| 08/30/2001 | US20010018440 L-beta-dioxolane uridine analogs and methods for treating and preventing virus infections |
| 08/30/2001 | US20010018212 Molecular weight of 14,000 to 24,000 daltons; treating infectious diseases and malignant tumors with said protein |
| 08/30/2001 | US20010018053 Methods for treating disease states comprising administration of low levels of antibodies |
| 08/30/2001 | US20010018050 Administering protein C; avoiding bleeding, toxicity and side effects of anticoagulant agents |
| 08/30/2001 | CA2683009A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2401113A1 Transporters and ion channels |
| 08/30/2001 | CA2401013A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 08/30/2001 | CA2400896A1 Novel compositions and uses of dictyostatin compounds |
| 08/30/2001 | CA2400831A1 Estrogen receptor beta variants and methods of detection thereof |
| 08/30/2001 | CA2400606A1 New phosphodiesterase type 7b |
| 08/30/2001 | CA2400485A1 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| 08/30/2001 | CA2400435A1 Novel compounds |
| 08/30/2001 | CA2400434A1 Novel compounds |
| 08/30/2001 | CA2400293A1 Novel compounds |
| 08/30/2001 | CA2400215A1 Hla binding peptides and their uses |
| 08/30/2001 | CA2400099A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 08/30/2001 | CA2399298A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2398275A1 Human polynucleotides, polypeptides, and antibodies |
| 08/30/2001 | CA2397813A1 Method and reagent for the inhibition of grid |
| 08/30/2001 | CA2396960A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | CA2365606A1 Medicament for prevention or treatment of various diseases involving an increase in eosinophils chymase inhibitor as effective ingredient |
| 08/29/2001 | EP1127883A2 Oxamides as IMPDH inhibitors |
| 08/29/2001 | EP1127869A1 Novel compounds and medicinal use thereof |
| 08/29/2001 | EP1127577A2 Ligand for the c-kit receptor and methods of use thereof |
| 08/29/2001 | EP1127115A1 Antisense oligomer |
| 08/29/2001 | EP1127110A1 Modified exosomes and uses |
| 08/29/2001 | EP1127109A2 The genetic determination of genes and its use for the prophylaxis and therapy of diseases |
| 08/29/2001 | EP1127107A1 Methods for the production of tcr gamma delta t cells |
| 08/29/2001 | EP1127076A2 Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof |
| 08/29/2001 | EP1127074A1 Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| 08/29/2001 | EP1127072A1 Method for detecting and purifying tcd8+ lymphocyte populations, specific of peptides present in the context of hla |
| 08/29/2001 | EP1127071A1 Compounds with growth hormone releasing properties |
| 08/29/2001 | EP1127064A1 Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof |
| 08/29/2001 | EP1127058A1 Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| 08/29/2001 | EP1127054A1 Novel inhibitors of impdh enzyme |
| 08/29/2001 | EP1127052A1 Substituted 2-phenylbenzimidazoles, the production thereof and their use |
| 08/29/2001 | EP1127051A2 Tricyclic pyrazole derivatives |
| 08/29/2001 | EP1126878A1 Heparanase activity neutralizing anti-heparanase monoclonal antibody |
| 08/29/2001 | EP1126876A2 Adjuvant systems and vaccines |
| 08/29/2001 | EP1126860A2 Immunomodulatory factors for immunosuppressant and antiallergic treatment |
| 08/29/2001 | EP1126854A1 Benzoazepines and analogs thereof useful as growth hormone secretagogues |
| 08/29/2001 | EP1126852A1 Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| 08/29/2001 | EP1126849A1 Heterocyclic potassium channel inhibitors |
| 08/29/2001 | EP1126843A1 Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
| 08/29/2001 | EP1126842A2 Inhibition of the formation of vascular hyperpermeability |
| 08/29/2001 | EP1126839A1 Substituted phenethylsulfones and method of reducing tnf alpha levels |
| 08/29/2001 | EP1126836A1 Benzamide potassium channel inhibitors |
| 08/29/2001 | EP1126828A1 Oral administration of adenosine analogs |
| 08/29/2001 | EP1126823A2 A process for the preparation of suspensions of drug particles for inhalation delivery |
| 08/29/2001 | EP0914043A4 Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof |
| 08/29/2001 | EP0904299B1 Synthetic polysaccharides, method for preparing same and pharmaceutical compositions containing said polysaccharides |
| 08/29/2001 | EP0825983B1 Process for the preparation of 2,2'-bipyrrolyl-pyrromethene (prodigiosins) derivatives |
| 08/29/2001 | EP0751709B1 Use of bcl-2 for the manufacture of medicaments for the therapeutic treatment and prevention of diseases |
| 08/29/2001 | CN1310759A Therapeutic and diagnostic domain 1 & beta 2GP1 polypeptides and methods of using same |
| 08/29/2001 | CN1310724A Novel peptides for use in immunotherapy of autoimmune diseases |
| 08/29/2001 | CN1310718A Heterocyclic compound as inhibitors of rotamase enzymes |
| 08/29/2001 | CN1310716A Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 08/29/2001 | CN1310715A Polymorph of ritonavir |
| 08/29/2001 | CN1310702A Nitric ester and nitrate salts of specific drugs |
| 08/29/2001 | CN1310626A Hybrid polypeptides with enhanced pharmacokinetic properties |
| 08/29/2001 | CN1310621A Substituted anilide compounds and methods |
| 08/29/2001 | CN1310179A Oxamide being as IMPDH inhibitor |
| 08/29/2001 | CN1310023A Specific immunological inhibitor |
| 08/29/2001 | CN1310022A Method of making medicine from extracting metabolic product of staphylococcus aureus and thallus protein |
| 08/29/2001 | CN1310013A Medicine for treating cardiovascular damage caused by systematic lupus erythematosus |
| 08/29/2001 | CN1310012A Medicine for treating fever caused by lupus erythematosus and other immunological disease |
| 08/29/2001 | CN1310011A Medicine for treating kidney damage caused by immunological disease lupus erythematosus |
| 08/29/2001 | CN1310010A Medicine for preventing and treating lupus erythematosus and other immunological disease |
| 08/29/2001 | CN1310009A Medicine for treating leucocytopenia caused by lupus erythematosus |
| 08/29/2001 | CN1310008A Lupus erythematosus treating medicine |
| 08/29/2001 | CN1310007A Detoxicating and recovering medicine powder |
| 08/29/2001 | CN1310006A Medicine for treating purpura caused by lupus erythematosus and other immunological disease |
| 08/29/2001 | CN1309997A Hualu health article and its preparation |
| 08/29/2001 | CN1309990A Perfume incense oil composition easy to be absorbed by body and its preparation and use |
| 08/29/2001 | CN1309970A Application of uridine phosphorylase inhibitor and composition containing the same |
| 08/29/2001 | CN1309965A New pharmaceutical use of sinomenine |
| 08/29/2001 | CN1070198C Isolated nucleic acid molecule of coded tumor rejection antigen precursor DAGE and its application |
| 08/28/2001 | US6281376 Therapeutic compound—fatty acid conjugates |
| 08/28/2001 | US6281363 Antiinflammatory agents; antiarthritic agents; autoimmune disorders |
| 08/28/2001 | US6281352 Antiinflammatory agents |
| 08/28/2001 | US6281230 Isoindolines, method of use, and pharmaceutical compositions |
| 08/28/2001 | US6281212 Chemokine receptor antagonists and methods of use therefor |
| 08/28/2001 | US6281193 In autoimmune diseases in general, or graft-versus-host reactions in particular. |
| 08/28/2001 | US6281012 Preventing graft versus host disease |
| 08/28/2001 | US6280978 Methods and compositions for use in spliceosome mediated RNA trans-splicing |